ReviewNature reviews. Disease primers2022
Trachoma.
Review in Nature reviews. Disease primers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Prevalence and Historical Trends of Trachoma in Egypt: A Systematic Review and Meta-Analysis.The Yale journal of biology and medicine · 2025Pooled it
- Pooled it
- The prevention and management of postoperative trachomatous trichiasis: A systematic review.Survey of ophthalmologyPooled it
- Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia.The Lancet. Global health · 2026Trial
- A Randomised Trial of Three Face-Washing Methods for the Removal of Chlamydia trachomatis From the Faces of Children With Severe Active Trachoma.Tropical medicine & international health : TM & IH · 2026Trial
- The FLuorometholone as Adjunctive MEdical Therapy for Trachomatous Trichiasis Surgery (FLAME) Trial: Study Design.Ophthalmic epidemiology · 2024Trial
- Gut Microbiome Diversity and Antimicrobial Resistance After a Single Dose of Oral Azithromycin in Children: A Randomized Placebo-Controlled Trial.The American journal of tropical medicine and hygiene · 2024Trial
- Single-dose azithromycin for infant growth in Burkina Faso: Prespecified secondary anthropometric outcomes from a randomized controlled trial.PLoS medicine · 2024Trial
- Split-GFP Reporter-Based Detection of Chlamydia trachomatis Inclusion Damage.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Experimental Evolution of Drug Resistance for Antibiotic Target Discovery in Chlamydia trachomatis.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Impact of two rounds of azithromycin mass drug administration on active trachoma and ocular Chlamydia trachomatis infection in Naoero.PLoS neglected tropical diseases · 2026Article
- Genome-wide association studies ofInfection and immunity · 2026Article
- Ocular community state types reveal distinct microbial compositions among microbiomes with implications for trachoma control.bioRxiv : the preprint server for biology · 2026Article
- Article
- The distinct trimeric structure of the immunodominant chlamydial antigen Major Outer Membrane Protein.Nature communications · 2026Article
- Comparing the Generalizability of Multiregional versus Locally Trained Deep Learning Models for Trachoma Detection.Ophthalmology science · 2026Article
- Article
- Developing strategies to address persistent and recrudescent trachoma in Ethiopia using the Delphi techniques.International health · 2026Article
- Dynamics of trachoma infection in West Africa revealed by a hidden state model.PLoS computational biology · 2026Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
Abstract
Trachoma is a neglected tropical disease caused by infection with conjunctival strains of Chlamydia trachomatis. It can result in blindness. Pathophysiologically, trachoma is a disease complex composed of two linked chronic processes: a recurrent, generally subclinical infectious-inflammatory disease that mostly affects children, and a non-communicable, cicatricial and, owing to trichiasis, eventually blinding disease that supervenes in some individuals later in life. At least 150 infection episodes over an individual's lifetime are needed to precipitate trichiasis; thus, opportunity exists for a just global health system to intervene to prevent trachomatous blindness. Trachoma is found at highest prevalence in the poorest communities of low-income countries, particularly in sub-Saharan Africa; in June 2021, 1.8 million people worldwide were going blind from the disease. Blindness attributable to trachoma can appear in communities many years after conjunctival C. trachomatis transmission has waned or ceased; therefore, the two linked disease processes require distinct clinical and public health responses. Surgery is offered to individuals with trichiasis and antibiotic mass drug administration and interventions to stimulate facial cleanliness and environmental improvement are designed to reduce infection prevalence and transmission. Together, these interventions comprise the SAFE strategy, which is achieving considerable success. Although much work remains, a continuing public health problem from trachoma in the year 2030 will be difficult for the world to excuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.